Mollon J, Reichenberg A. Cognitive development prior to onset of psychosis. Psychol Med. 2018;48(3):392–403.

Article  CAS  PubMed  Google Scholar 

Green MF, Horan WP, Lee J. Nonsocial and social cognition in schizophrenia: current evidence and future directions. World Psychiatry. 2019;18(2):146–61.

Article  PubMed  PubMed Central  Google Scholar 

Stone WS, Cai B, Liu X, Grivel MM, Yu G, Xu Y, Ouyang X, Chen H, Deng F, Xue F, et al. Association between the duration of untreated psychosis and selective cognitive performance in Community-Dwelling individuals with chronic untreated Schizophrenia in Rural China. JAMA Psychiatry. 2020;77(11):1116–26.

Article  PubMed  Google Scholar 

Millman ZB, Roemer C, Vargas T, Schiffman J, Mittal VA, Gold JM. Neuropsychological performance among individuals at clinical high-risk for psychosis vs putatively low-risk peers with other psychopathology: a systematic review and Meta-analysis. Schizophr Bull. 2022;48(5):999–1010.

Article  PubMed  PubMed Central  Google Scholar 

Hedges EP, See C, Si S, McGuire P, Dickson H, Kempton MJ. Meta-analysis of longitudinal neurocognitive performance in people at clinical high-risk for psychosis. Psychol Med. 2022;52(11):2009–16.

Article  PubMed  PubMed Central  Google Scholar 

Cui H, Giuliano AJ, Zhang T, Xu L, Wei Y, Tang Y, Qian Z, Stone LM, Li H, Whitfield-Gabrieli S, et al. Cognitive dysfunction in a psychotropic medication-naive, clinical high-risk sample from the ShangHai-At-Risk-for-psychosis (SHARP) study: associations with clinical outcomes. Schizophr Res. 2020;226:138–46.

Article  PubMed  Google Scholar 

Desamericq G, Schurhoff F, Meary A, Szoke A, Macquin-Mavier I, Bachoud-Levi AC, Maison P. Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur J Clin Pharmacol. 2014;70(2):127–34.

Article  CAS  PubMed  Google Scholar 

Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology. 2003;28(8):1491–500.

Article  CAS  PubMed  Google Scholar 

Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res. 2001;48(1):17–28.

Article  CAS  PubMed  Google Scholar 

Husa AP, Rannikko I, Moilanen J, Haapea M, Murray GK, Barnett J, Jones PB, Isohanni M, Koponen H, Miettunen J, et al. Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia—an observational 9-year follow-up study. Schizophr Res. 2014;158(1–3):134–41.

Article  PubMed  Google Scholar 

Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, Watanabe K, Mimura M, Uchida H. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull. 2013;39(5):993–8.

Article  PubMed  PubMed Central  Google Scholar 

Albert N, Randers L, Allott K, Jensen HD, Melau M, Hjorthoj C, Nordentoft M. Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial. Psychol Med. 2019;49(7):1138–47.

Article  PubMed  Google Scholar 

Faber G, Smid HG, Van Gool AR, Wiersma D, Van Den Bosch RJ. The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis. Eur Psychiatry. 2012;27(4):275–80.

Article  CAS  PubMed  Google Scholar 

Singh A, Kumar V, Pathak H, Jacob AA, Venkatasubramanian G, Varambally S, Rao NP. Effect of antipsychotic dose reduction on cognitive function in schizophrenia. Psychiatry Res. 2022;308:114383.

Article  CAS  PubMed  Google Scholar 

Zhang T, Cui H, Wei Y, Tang X, Xu L, Hu Y, Tang Y, Chen T, Li C, Wang J. Neurocognitive assessments are more important among adolescents than adults for Predicting psychosis in clinical high risk. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022;7(1):56–65.

CAS  PubMed  Google Scholar 

Zhang T, Raballo A, Zeng J, Gan R, Wu G, Wei Y, Xu L, Tang X, Hu Y, Tang Y, et al. Antipsychotic prescription, assumption and conversion to psychosis: resolving missing clinical links to optimize prevention through precision. Schizophrenia (Heidelb). 2022;8(1):48.

Article  CAS  PubMed  Google Scholar 

Zhang T, Xu L, Tang X, Wei Y, Hu Q, Hu Y, Cui H, Tang Y, Hui L, Li C, et al. Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai at risk for psychosis). Aust N Z J Psychiatry. 2020;54(7):696–706.

Article  PubMed  Google Scholar 

Zhang T, Xu L, Wei Y, Tang X, Hu Y, Cui H, Tang Y, Xie B, Li C, Wang J. When to initiate antipsychotic treatment for psychotic symptoms: at the premorbid phase or first episode of psychosis? Aust N Z J Psychiatry. 2021;55(3):314–23.

Article  PubMed  Google Scholar 

Zhang T, Tang X, Zhang Y, Xu L, Wei Y, Hu Y, Cui H, Tang Y, Liu H, Chen T, et al. Multivariate joint models for the dynamic prediction of psychosis in individuals with clinical high risk. Asian J Psychiatr. 2023;81:103468.

Article  PubMed  Google Scholar 

Zhang T, Zeng J, Wei Y, Ye J, Tang X, Xu L, Hu Y, Cui H, Xie Y, Tang Y, et al. Changes in inflammatory balance correlates with conversion to psychosis among individuals at clinical high-risk: a prospective cohort study. Psychiatry Res. 2022;318:114938.

Article  CAS  PubMed  Google Scholar 

Zhang T, Wang J, Xu L, Wei Y, Tang X, Hu Y, Cui H, Tang Y, Li C, Ling Z, et al. Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals. Eur Arch Psychiatry Clin Neurosci. 2022;272(4):591–602.

Article  PubMed  Google Scholar 

Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703–15.

Article  PubMed  Google Scholar 

Zhang T, Li H, Woodberry KA, Seidman LJ, Zheng L, Li H, Zhao S, Tang Y, Guo Q, Lu X, et al. Prodromal psychosis detection in a counseling center population in China: an epidemiological and clinical study. Schizophr Res. 2014;152(2–3):391–9.

Article  PubMed  Google Scholar 

Zhang TH, Li HJ, Woodberry KA, Xu LH, Tang YY, Guo Q, Cui HR, Liu XH, Chow A, Li CB, et al. Two-year follow-up of a Chinese sample at clinical high risk for psychosis: timeline of symptoms, help-seeking and conversion. Epidemiol Psychiatr Sci. 2017;26(3):287–98.

Article  CAS  PubMed  Google Scholar 

Zheng L, Wang J, Zhang T, Li H, Li C, Jiang K. The Chinese version of the SIPS/SOPS: a pilot study of reliability and validity. Chin Mental Health J. 2012;26(8):571–6.

Google Scholar 

Zhang T, Tang X, Li H, Woodberry KA, Kline ER, Xu L, Cui H, Tang Y, Wei Y, Li C, et al. Clinical subtypes that predict conversion to psychosis: a canonical correlation analysis study from the ShangHai at risk for psychosis program. Aust N Z J Psychiatry. 2020;54(5):482–95.

Article  PubMed  Google Scholar 

Zhang T, Xu L, Tang Y, Li H, Tang X, Cui H, Wei Y, Wang Y, Hu Q, Liu X, et al. Prediction of psychosis in prodrome: development and validation of a simple, personalized risk calculator. Psychol Med. 2019;49(12):1990–8.

Article  PubMed  Google Scholar 

Zhang T, Li H, Tang Y, Niznikiewicz MA, Shenton ME, Keshavan MS, Stone WS, McCarley RW, Seidman LJ, Wang J. Validating the predictive accuracy of the NAPLS-2 psychosis risk calculator in a clinical high-risk sample from the SHARP (Shanghai at risk for psychosis) program. Am J Psychiatry. 2018;175(9):906–8.

Article  PubMed  Google Scholar 

Kern RS, Gold JM, Dickinson D, Green MF, Nuechterlein KH, Baade LE, Keefe RS, Mesholam-Gately RI, Seidman LJ, Lee C, et al. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res. 2011;126(1–3):124–31.

Article  PubMed  Google Scholar 

Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, et al. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008;165(2):214–20.

Article  PubMed  Google Scholar 

Shi C, He Y, Cheung EF, Yu X, Chan RC. An ecologically valid performance-based social functioning assessment battery for schizophrenia. Psychiatry Res. 2013;210(3):787–93.

Article  PubMed  Google Scholar 

Leucht S, Samara M, Heres S, Davis JM. Dose equivalents for antipsychotic drugs: the DDD Method. Schizophr Bull. 2016;42(Suppl 1):S90–94.

Article  PubMed  PubMed Central  Google Scholar 

Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, Barbui C, Leucht S, Furukawa TA. Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials. J Affect Disord. 2015;180:179–84.

Article  CAS  PubMed  Google Scholar 

Zhang T, Xu L, Li H, Cui H, Tang Y, Wei Y, Tang X, Hu Y, Hui L, Li C, et al. Individualized risk components guiding antipsychotic delivery in patients with a clinical high risk of psychosis: application of a risk calculator. Psychol Med. 2021;51:1–10.

Article  CAS  Google Scholar 

Ziermans TB, Schothorst PF, Sprong M, van Engeland H. Transition and remission in adolescents at ultra-high risk for psychosis. Schizophr Res. 2011;126(1–3):58–64.

Article  PubMed  Google Scholar 

Yoviene Sykes LA, Ferrara M, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Perkins DO, Mathalon DH, Seidman LJ, et al. Predictive validity of conversion from the clinical high risk syndrome to frank psychosis. Schizophr Res. 2020;216:184–91.